REFERENCES
- World Health Organization. Coronavirus disease (COVID-19) pandemic.
2020.
https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov.
Accessed 10 July, 2020.
- World Health Organization. Coronavirus disease (COVID-2019) situation
reports-173. Geneva: WHO; 2020.
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200711-covid-19-sitrep-173.pdf?sfvrsn=949920b4_2.
Accessed 11 July, 2020.
- Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of
mortality due to COVID-19 based on an analysis of data of 150 patients
from Wuhan, China. Intensive Care Med . 2020;46(5):846-848.
- Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious
COVID-19: A Promising Therapy? Pharmaceut Med . 2020:1-9.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics
of patients dying in relation to COVID-19 in Italy [JAMA Network].
https ://jaman etwor k.com/journ als/jama/fulla rticl e/27636 67.
Accessed 29 April, 2020.
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: a descriptive study. Lancet .
2020;395(10223):507‐513.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet .
2020;395(10223):497‐506.
- Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in
COVID-19: A single center experience. J Med Virol .
2020;92(7):814-818.
- Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and
disease. Nat Immunol . 2015;16(5):448-457.
- Wang WK, Chen SY, Liu IJ, et al. Severe Acute Respiratory Syndrome
Research Group of the National Taiwan University College of
Medicine/NTU Hospital. Temporal relationship of viral load, ribavirin,
interleukin (IL)-6, IL-8, and clinical progression in patients with
severe acute respiratory syndrome. Clin Infect Dis .
2004;39(7):1071-1075.
- Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential
treatment for 2019-nCoV acute respiratory disease. Lancet .
2020;395(10223):e30-e31.
- Cingolani A, Tummolo AM, Montemurro G, et al. Baricitinib as rescue
therapy in a patient with COVID-19 with no complete response to
sarilumab. Infection . 2020:1-5.
- Kubo S, Nakayamada S, Sakata K, et al. Janus kinase inhibitor
baricitinib modulates human innate and adaptive immune system.Front Immunol . 2018;9:1510.
- Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D.
Baricitinib therapy in COVID-19: A pilot study on safety and clinical
impact. J Infect . 2020:S0163-4453(20)30228-0.
- Bronte V, Ugel S, Tinazzi E, et al. Baricitinib restrains the immune
dysregulation in COVID-19 patients. 2020.
https://doi.org/10.1101/2020.06.26.20135319
- World Health Organization. Clinical management of COVID-19. Interim
guidance. 2020.
https://www.who.int/publications/i/item/clinical-management-of-covid-19.
Accessed 21 July, 2020.
- Archer SL, Sharp WW, Weir EK. Differentiating COVID-19 pneumonia from
acute respiratory distress syndrome and high altitude pulmonary edema.Circulation . 2020;142(2):101-104.
- Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of
kinase inhibitor selectivity. Nat Biotechnol .
2008;26(1):127-132.
- Kim H, Brooks KM, Tang CC, et al. Pharmacokinetics, pharmacodynamics,
and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in
pediatric and young adult CANDLE and SAVI Patients. Clin
Pharmacol Ther . 2018;104(2):364-373.
- McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib,
upadacitinib, and tofacitinib mediated regulation of cytokine
signaling in human leukocyte subpopulations. Arthritis Res
Ther . 2019;21(1):183.
- Perricone C, Triggianese P, Bartoloni E, et al. The anti-viral facet
of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun .
2020;111:102468.